Last reviewed · How we verify
Valsartan 80 mg
Valsartan 80 mg, marketed by Mostafa Bahaa, is an established treatment in the cardiovascular segment with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and long-term use in treating hypertension. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Valsartan 80 mg |
|---|---|
| Also known as | Valsartan, Nebivolol/Valsartan 5/80mg |
| Sponsor | Mostafa Bahaa |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (PHASE3)
- Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A (PHASE3)
- An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan
- A Multicenter, Randomized, Double-Blind Phase 3 Trial of KDF1901 in Patients With Essential Hypertension (PHASE3)
- Role of ARNi in Ventricular Remodeling in Hypertensive LVH (PHASE2)
- LCZ696 in Advanced LV Hypertrophy and HFpEF (PHASE2)
- PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valsartan 80 mg CI brief — competitive landscape report
- Valsartan 80 mg updates RSS · CI watch RSS
- Mostafa Bahaa portfolio CI